p53 mutation in the genesis of metastasis
- PMID: 25201191
- DOI: 10.1007/978-94-017-9211-0_6
p53 mutation in the genesis of metastasis
Abstract
Development of metastatic cancer is a complex series of events that includes genesis of tumor-related vascular and lymphatic systems, enhanced cellular motility, and the capacity to invade and survive at distant sites, as well as evasion of host defences. The wild-type p53 protein plays key roles in controlling these facets of tumor progression, and loss of normal p53 function can be sufficient to predispose tumor cells to gain metastatic properties. In contrast, dominant p53 mutants that have gained oncogenic functions can actively drive metastasis through a variety of mechanisms. This chapter aims to highlight these processes.
Similar articles
-
Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53.Oncogene. 2003 May 15;22(19):2960-6. doi: 10.1038/sj.onc.1206405. Oncogene. 2003. PMID: 12771947
-
Induction of genetic instability by gain-of-function p53 cancer mutants.Oncogene. 2008 Jun 5;27(25):3501-7. doi: 10.1038/sj.onc.1211023. Epub 2008 Jan 28. Oncogene. 2008. PMID: 18223686 Review.
-
Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells.Oncogene. 1996 May 2;12(9):2035-9. Oncogene. 1996. PMID: 8649865
-
Distant metastases in ovarian cancer: association with p53 mutations.Clin Cancer Res. 1999 Sep;5(9):2485-90. Clin Cancer Res. 1999. PMID: 10499623
-
Gain-of-function mutations in the tumor suppressor gene p53.Clin Cancer Res. 2000 Jun;6(6):2138-45. Clin Cancer Res. 2000. PMID: 10873062 Review.
Cited by
-
Pleiotropic functions of miR107 in cancer networks.Onco Targets Ther. 2018 Jul 18;11:4113-4124. doi: 10.2147/OTT.S151236. eCollection 2018. Onco Targets Ther. 2018. PMID: 30140157 Free PMC article. Review.
-
Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation: A case report.Medicine (Baltimore). 2017 Nov;96(47):e8744. doi: 10.1097/MD.0000000000008744. Medicine (Baltimore). 2017. PMID: 29381967 Free PMC article.
-
Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine.BMC Med Genomics. 2020 Sep 21;13(1):138. doi: 10.1186/s12920-020-00794-x. BMC Med Genomics. 2020. PMID: 32957974 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous